title: Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter.
abstract: Mechanisms to maintain blood pressure in the face of infection are critical to survival. The angiotensinogen (AGT) gene locus is an important component of this response. Thus the AGT gene, expressed predominantly by liver cells, is known to be a positive acute phase reactant. We have previously demonstrated activation of the AGT promoter in hepatocytes through the IL6/STAT3 signaling mechanism. We have now investigated whether IFN-gamma, a cytokine also induced in response to diverse infections, can regulate AGT gene expression, and have elucidated the molecular mechanism involved. IFN gamma treatment up-regulated AGT mRNA level and promoter activity in Hep3B hepatocytes. Sequential deletion of the promoter from the 5' side suggested the major IFN gamma responsive DNA element to be between -303 and -103. This region contained a candidate STAT1-binding site between -271 and -279. EMSA and chromatin immuno-precipitation (ChIP) assays confirmed that IFN-gamma treatment induced the binding of STAT1 to this element. Reporter constructs containing this AGT promoter derived element in a multimerized context but not a mutant version were responsive to IFN gamma. Moreover mutating this STAT1 element in the context of the wild-type AGT holo promoter reduced responsiveness to IFN gamma. In contrast to the clear synergism between dexamethasone and IL 6 in the upregulation of the AGT promoter (through interaction between GR and STAT3), the combination of IFN gamma with IL 6 or with dexamethasone did not further increase AGT promoter activity suggesting that the IFN gamma/STAT1 pathway represents a separate signaling mechanism. These data highlight the redundancy in cytokine-mediated host response pathways aimed at the maintenance of blood pressure during infection.
authors.affiliation: Department of Pathology, New York Medical College, Rm 455, Basic Science Building, Valhalla, NY 10595, USA.
authors.forename: Sudhir
authors.initials: S
authors.lastname: Jain
authors.forename: Mehul
authors.initials: M
authors.lastname: Shah
authors.forename: Yanna
authors.initials: Y
authors.lastname: Li
authors.forename: Govindaiah
authors.initials: G
authors.lastname: Vinukonda
authors.forename: Pravin B
authors.initials: PB
authors.lastname: Sehgal
authors.forename: Ashok
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000808:Angiotensinogen / Q000235:genetics*; D001665:Binding Sites; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D024202:Electrophoretic Mobility Shift Assay; D005786:Gene Expression Regulation; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000187:drug effects; D020218:Response Elements / Q000187:drug effects; D050794:STAT1 Transcription Factor / Q000378:metabolism*; D017384:Sequence Deletion; D014158:Transcription, Genetic / Q000187:drug effects*; D015854:Up-Regulation
chemical_list: D015850:Interleukin-6; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D000808:Angiotensinogen; D007371:Interferon-gamma